- PR Newswire•4 days agoInfinity Presents Preclinical Data and Phase 1 Clinical Data on IPI-549 at PI3K Keystone Symposia Conference
CAMBRIDGE, Mass., Jan. 20, 2017 /PRNewswire/ -- Today, during a plenary session at the Keystone Symposia Conference, "PI3K Pathways in Immunology, Growth Disorders and Cancer," Infinity Pharmaceuticals, ...
- PR Newswire•15 days ago
CAMBRIDGE, Mass., Jan. 9, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today outlined anticipated milestones for IPI-549, a potentially first-in-class immuno-oncology product candidate ...
- TheStreet.com•16 days ago
Insiders at Infinity Pharmaceuticals and Och-Ziff Capital Management Group -- among other companies -- have been scooping up shares of their own stock lately.
INFI : Summary for Infinity Pharmaceuticals, Inc. - Yahoo Finance
Infinity Pharmaceuticals, Inc. (INFI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||2.06 x 1700|
|Ask||2.07 x 1500|
|Day's Range||1.95 - 2.10|
|52 Week Range||0.84 - 6.97|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.22|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|